DOUBLE-BLIND, ONE YEAR PARALLEL GROUPS STUDY CONTROLLED WITH ACTIVE COMPARATOR AND CARRIED OUT IN BLIND CONDITIONS TO EVALUATE THE SAFETY AND EFFICACY OF MK-966 (L-748, 731) IN PURCHASE WITH SODIUM DICLOFENACO IN PATIENTS WITH KNEE AND HIP OSTEOARTHRITIS

计划入组 0 人

An international, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, 52-week gastrointestinal clinical safety study to demonstrate that COX189 (400 mg od) reduces the risk to develop complicated ulcers as compared to NSAlDs (naproxen 500 mg bid and ibuprofen 800 mg tid), in rheumatoid arthritis and osteoarthritis patients

计划入组 0 人

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

计划入组 53 人 · 首次发布于 2022 年 6 月 6 日

SDGR-1

SGR-1505

Wee1 kinase inhibitors(Schrodinger)

Schrodinger

United States

Schrödinger Co-Founds Tectora Therapeutics with $55M Series A to Advance Immunology and Inflammation Programs

Schrödinger to Present Phase 1 Data on MALT1 Inhibitor SGR-1505 for Relapsed/Refractory B-Cell Malignancies

Schrödinger Reports 63% Revenue Growth in Q1 2025, Prepares to Share Clinical Data for SGR-1505